The Ohio State University, Department of Neurology, Columbus, OH, USA.
Expert Opin Pharmacother. 2012 Jan;13(1):111-4. doi: 10.1517/14656566.2012.643869.
Despite several available therapeutic options to treat the symptoms of Parkinson's disease (PD), there are currently no agents that halt or slow the progression of disease. Istradefylline is a selective adenosine A(2A) antagonist that is currently of interest for the treatment of motor complications in PD.
This paper reviews the limitations of currently available treatment options and discusses the results seen in both animal models and human clinical trials that have explored the benefits of istradefylline in PD.
The studies outlined continue to suggest that istradefylline may be a promising non-dopaminergic therapy for the treatment of PD. It has not been proven to be more efficacious than other currently available dopaminergic drugs, nor has it been shown to be of significant benefit as monotherapy; however, it seems to be a safe and well-tolerated drug that may help with wearing-off fluctuations. Istradefylline is not yet an FDA-approved drug. At this time, the potential for approval in the US or through the European Medical Agency remains unknown.
尽管有几种治疗帕金森病（PD）症状的方法，但目前尚无能够阻止或减缓疾病进展的药物。依曲替酯是一种选择性的腺苷 A（2A）拮抗剂，目前对治疗 PD 的运动并发症很有研究价值。
本文回顾了目前可用的治疗选择的局限性，并讨论了在探索依曲替酯在 PD 中的益处的动物模型和人体临床试验中观察到的结果。
所概述的研究继续表明，依曲替酯可能是一种有前途的非多巴胺能治疗 PD 的方法。它尚未被证明比其他目前可用的多巴胺能药物更有效，也没有显示出作为单一疗法的显著益处；然而，它似乎是一种安全且耐受性良好的药物，可能有助于缓解波动。依曲替酯尚未获得 FDA 批准。目前，在美国或通过欧洲药品管理局获得批准的可能性尚不清楚。
